SARS-CoV-2/COVID-19 and advances in develo** potential therapeutics and vaccines to counter this emerging pandemic
A novel coronavirus (SARS-CoV-2), causing an emerging coronavirus disease (COVID-19),
first detected in Wuhan City, Hubei Province, China, which has taken a catastrophic turn with …
first detected in Wuhan City, Hubei Province, China, which has taken a catastrophic turn with …
Assessment and management of asymptomatic COVID-19 infection: A systematic review
Background COVID-19 can be asymptomatic in a substantial proportion of patients. The
assessment and management of these patients constitute a key element to stop …
assessment and management of these patients constitute a key element to stop …
Prescription, over-the-counter (OTC), herbal, and other treatments and preventive uses for COVID-19
JA Yáñez, SA Chung, BR Román… - … and health management …, 2021 - Elsevier
The current COVID-19 pandemic has spread rapidly worldwide and has challenged fragile
health care systems, vulnerable socioeconomic conditions, and population risk factors, and …
health care systems, vulnerable socioeconomic conditions, and population risk factors, and …
[HTML][HTML] Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy
WR Geisen, J Berger, C Schwartz, A Reddy, B Rai… - IDCases, 2020 - Elsevier
Abstract The novel coronavirus-2019 (COVID-19) has caused a global pandemic of
historical proportions, infecting millions of people worldwide. Due to its high mortality rate …
historical proportions, infecting millions of people worldwide. Due to its high mortality rate …
Cytomegalovirus and severe acute respiratory syndrome coronavirus 2 Co-infection in renal transplants: a retrospective study from a single center
HS Meshram, VB Kute, H Patel… - Saudi Journal of …, 2021 - journals.lww.com
There is a scarcity of data regarding the impact of cytomegalovirus (CMV) infection
complicating the coronavirus disease-2019 (COVID-19) course. The objective of the study …
complicating the coronavirus disease-2019 (COVID-19) course. The objective of the study …
Spotlight on Immunity against COVID-19 with Emphasis on Cytokine Storm
AM Aldahlawi, KSA Zaher - Pharmacophore, 2021 - pharmacophorejournal.com
In December 2019, in China, a novel coronavirus (n-CoV-2) appeared causing global panic
and called COVID-19 or SARS-CoV-2. It has spread to more than 210 counties and is …
and called COVID-19 or SARS-CoV-2. It has spread to more than 210 counties and is …
Gastrointestinal Manifestations of COVID-19 and Inflammatory Bowel Disease in the COVID-19 Era: Clinical Overview and Updated Guidelines
S El-Nakeep - Frontiers of COVID-19: Scientific and Clinical Aspects …, 2022 - Springer
Aim: The aim of this chapter is to discuss the gastrointestinal (GI) manifestations of
coronavirus (COVID-19) and inflammatory bowel disease (IBD) in the pandemic era …
coronavirus (COVID-19) and inflammatory bowel disease (IBD) in the pandemic era …
A brief introduction to coronavirus disease 2019 (COVID-19) and the roles of zoonotic spillover
Coronaviruses are eminently present in animals since they were discovered over half a
century ago. In 2002 and 2012 two major zoonoticemerging epidemics occurred in Asia, the …
century ago. In 2002 and 2012 two major zoonoticemerging epidemics occurred in Asia, the …
Диарейный синдром при инфекции, вызванной SARS-CoV-2, у детей
МК Хадисова, СВ Лёгкий - StatusPraesens. Педиатрия и неонатология, 2020 - elibrary.ru
В мае 2020 года исследователи из Китая опубликовали результаты наблюдения за
детьми, поступавшими в стационар без явных признаков респираторной инфекции, у …
детьми, поступавшими в стационар без явных признаков респираторной инфекции, у …
[PDF][PDF] Consensus Guidelines in Usage of Biologics in Dermatology during COVID-19 Pandemic: Biologic Advisory Group Malaysia
SKW Chow, SE Choon, CL Chin… - Malaysian Journal of …, 2020 - dermatology.org.my
Objective The aim of this Biologic Advisory Group (BAG) Malaysia consensus guideline is to
provide clinicians managing cutaneous diseases with biologics relevant parameters to …
provide clinicians managing cutaneous diseases with biologics relevant parameters to …